20Feb 2024
Regorafenib–Nivolumab Combo for uHCC Patients

Regorafenib–Nivolumab Combo for uHCC Patients

The study evaluated regorafenib–nivolumab combination therapy as front-line treatment for unresectable hepatocellular carcinoma (uHCC). Of the 42 patients treated, the objective response rate (ORR) per RECIST version 1.1 was 31.0%, meeting the primary endpoint. Median progression-free survival (PFS) was 7.38 months, and 1-year overall survival (OS) rate was 80.5%. Exploratory analyses suggested immune biomarkers of response, supporting further development of this combination therapy for uHCC.

  • #oncology

Like

Save

Share